anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To obtain a cosmetic by combining specific components, having an excellent feeling in use and in finish. CONSTITUTION: This cosmetic for hair comprises a 14-22C straight-chain alkyl group-containing higher alcohol, a cationic surfactant, a polyglycerol fatty acid ester having >=7 HLB and a polyhydric alcohol. The system may be mixed with a silicon derivative. The higher alcohol, for example, includes lauryl alcohol, cetyl alcohol, etc., and its amount is preferably 1-10wt.% in the cosmetic for hair. The cationic surfactant includes an alkyltrimethylammonium chloride, etc., and its amount is preferably 0.5-10wt.%. A decaglycerol difatty acid ester is preferable as the polyglycerol fatty acid ester and its amount is preferably 0.5-5wt.%. Ethylene glycol, etc., may be cited as the polyhydric alcohol. Dimethylpolysiloxane may be cited as the silicon derivative.
Single agent dose escalation of AC176. AC176 will be given orally (PO) on a 28-day cycle.
Patients who have previously been vaccinated with Melan-A/MART-1 peptide are eligible. Whole PBMC's containing Melan-A specific CD8+ lymphocytes are collected via lymphocytapheresis and freezed. Lymphodepleting chemotherapy consists of 2 days of Busulfan 2mg/kg at days -7,-6, followed by Fludarabine 30mg/m2 at days -5,-4,-3. At day 0, whole untreated PBMC's are reinfused to the patient and vaccination with Melan-A analog peptide is restarted and repeated every 4 weeks. Immunomonitoring with detailed FACS analysis using tetramers is performed at day 0,8,15,30, and then monthly. The aim is to boost Melan-A specific CD8 T cells in vivo during homeostatic proliferation after lymphodepletion and antigen driven proliferation due to peptide vaccination.
This clinical trial, a prospective, focuses on patients with ST-Elevation Myocardial Infarction (STEMI) requiring Percutaneous Coronary Intervention (PCI) within 12 hours of onset. The study aims to control bias effectively through randomization, evenly distributing confounding factors across two groups. Patients, unknown to both researchers and themselves whether receiving Colchicine or a placebo, will undergo reperfusion therapy and optimal medicinal treatment according to the latest guidelines. The study population includes all STEMI patients in three cities in East Java (Jember, Malang, Tulungagung), selected through purposive sampling. The independent variable is Colchicine administration, while dependent variables include ventricular remodeling assessed by Left Ventricular End-Diastolic Volume (LVEDV) via echocardiography, serum levels of caspase-1, TGF-β, NT pro BNP and Galectin-3. All patients receive standard medical treatment pre-PCI, including aspirin and antiplatelet drugs, with post-PCI Optical Medical Treatment (OMT) following the latest guidelines.

The trial is randomized, double-blinded, and placebo-controlled, with participants divided into four groups: early PCI with Colchicine or placebo, and STEMI without reperfusion, receiving either Colchicine or placebo. This setup allows for a comprehensive comparison across different patient management strategies, exploring Colchicine's potential benefits in post-AMI care and its effects on key inflammatory and fibrotic markers.
BACKGROUND: Hemoptysis is a challenging and potentially life-threatening medical condition. The most appropriate diagnostic work-up is debated and several diagnostic approaches are implemented worldwide.
METHODS: An international, online survey was carried out to investigate the current practice of the diagnostic work-up of patients with hemoptysis of unknown etiology.
RESULTS: Overall, 604 physicians responded to the survey. At baseline, chest X-ray was suggested as the first diagnostic investigation by 342 (56.6%) participants. Computed tomography (CT) was suggested in each patient with non- and life-threatening hemoptysis by 310 (51.3%) and 526 (87.1%) respondents, respectively. Contrast-enhanced CT is the currently preferred technique (333, 55.1%). In case of patchy ground glass opacities and negative CT, 287 (47.5%) and 222 (36.8%) participants, respectively, would always offer bronchoscopy. Otorhinolaryngological evaluation was mostly suggested in case of suspected upper airways bleeding before other investigations (212, 35.1%). A follow-up was recommended for idiopathic hemoptysis by the majority of the participants (316, 52.3%). A multidisciplinary assessment is deemed crucial for each patient with life-threatening hemoptysis (437, 72.4%).
CONCLUSIONS: Chest X-ray and contrast-enhanced CT are currently preferred as the first diagnostic investigations, regardless of hemoptysis severity. Bronchoscopy is suggested in case of negative radiological examination and when CT shows only ground glass opacities. Otorhinolaryngological evaluation is advised before any other investigations when upper airways bleeding is suspected. Patients with idiopathic hemoptysis are suggested to undergo a clinical follow-up and in case of life-threatening bleeding a multidisciplinary assessment is deemed crucial. Due to the heterogeneous approaches a consensus statement would be needed.
Fentanyl 2 ml (100 μg) will be mixed with 48 ml bupivacaine 0.125% in an elastomeric pump. The rate of epidural infusion will be 5ml/hr for the postoperative 24 hours.
Start therapy with estradiol transdermal system (twice-weekly) 0.0375 mg per day applied to the skin twice weekly. Make dosage adjustments based on the clinical response. Initiate estradiol transdermal system (twice-weekly) at once in a woman not currently taking oral estrogens or in a woman switching from another estradiol transdermal therapy. In women who are currently taking oral estrogens, initiate treatment with estradiol transdermal system (twice-weekly) 1 week after withdrawal of oral hormone therapy, or sooner if menopausal symptoms reappear in less than 1 week. Attempts to taper or discontinue estradiol transdermal system (twice-weekly) at 3 to 6-month intervals.

Give estradiol transdermal system (twice-weekly) continuously in a woman who does not have an intact uterus. In a woman with an intact uterus, give estradiol transdermal system (twice-weekly) on a cyclic schedule (for example, 3 weeks on estradiol transdermal system (twice-weekly) followed by 1 week off estradiol transdermal system (twice-weekly)).
The chewing sticks are under the brand of Al-Khair. They will be prepared into equal length of 15 cm with uniform diameter of 1.0-1.5 cm and are sealed in airtight plastic bags. Participants are expected to use this oral hygiene tool for 3 weeks.
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to surgery. During the operation, a drainage tube is installed in the lower third of the esophagus in the area of ​​surgery. In the postoperative period, when saliva or small intestinal contents appear in the drainage tube, the tube is connected to an aspirator for negative pressure treatment. Vacuum aspiration is carried out in a continuous mode according to the scheme: the first 10 days of treatment, vacuum aspiration is carried out at a negative pressure of 100 mm Hg. In this case, daily 3 times a day, vacuum aspiration is stopped for 10 minutes. At this time, 50 ml of Miramistin are administered orally to the patient, as well as into the drainage tube. For the next 7 days, vacuum aspiration is performed at a negative pressure of 70 mm Hg. In this case, every day, 2 times a day, vacuum aspiration is stopped for 10 minutes. At this time, 30 ml of Miramistin are administered orally to the patient, as well as into the drainage tube. In the following days of treatment, the administration of Miramistin is stopped, and vacuum aspiration is carried out at a negative pressure of 50 mm Hg. until the esophageal-mediastinal-cutaneous fistula is completely closed, after which the drainage tube is removed. The course of treatment is 20-25 days.EFFECT: method is low-traumatic, non-invasive, allows effective treatment of esophageal-mediastinal-cutaneous fistula after operations in the lower third, does not require repeated surgery.1 cl, 3 ex
Spontaneous intracerebral hemorrhage (ICH) is a very serious kind of stroke. If the outcome of patients can be accurately assessed at the early stage of disease occurrence, it will be of great significance to the patients and clinical treatment. The present study was conducted to investigate whether non-contrast computer tomography (NCCT) models of hematoma and perihematomal tissues could improve the accuracy of short-term prognosis prediction in ICH patients with conservative treatment. In this retrospective analysis, a total of 166 ICH patients with conservative treatment during hospitalization were included. Patients were randomized into a training group (N = 132) and a validation group (N = 34) in a ratio of 8:2, and the functional outcome at 90 days after clinical treatment was assessed by the modified Rankin Scale (mRS). Radiomic features of hematoma and perihematomal tissues of 5 mm, 10 mm, 15 mm were extracted from NCCT images. Clinical factors were analyzed by univariate and multivariate logistic regression to identify independent predictive factors. In the validation group, the mean area under the ROC curve (AUC) of the hematoma was 0.830, the AUC of the perihematomal tissue within 5 mm, 10 mm, 15 mm was 0.792, 0.826, 0.774, respectively, and the AUC of the combined model of hematoma and perihematomal tissue within 10 mm was 0.795. The clinical-radiomics nomogram consisting of five independent predictors and radiomics score (Rad-score) of the hematoma model were used to assess 90-day functional outcome in ICH patients with conservative treatment. Our findings found that the hematoma model had better discriminative efficacy in evaluating the early prognosis of conservatively managed ICH patients. The visual clinical-radiomics nomogram provided a more intuitive individualized risk assessment for 90-day functional outcome in ICH patients with conservative treatment. The hematoma could remain the primary therapeutic target for conservatively managed ICH patients, emphasizing the need for future clinical focus on the biological significance of the hematoma itself.
To suppress a harsh taste characteristic of Salacia plant extracts.SOLUTION: An oral composition comprises a Salacia plant extract and naringin, wherein the naringin is 0.001-6 pts.wt. per pt.wt. (in terms of a dry material) of the Salacia plant extract. A method for ameliorating a harsh taste of the Salacia plant extracts is characterized by combining the naringin at 0.001-6 pts.wt. per pt.wt. (in terms of the dry material) of the Salacia plant extract.SELECTED DRAWING: None
OBJECTIVE: Acute intracerebral hemorrhage (AICH) and cerebral cavernous hemangioma (CCM) are two common cerebral hemorrhage diseases with partially overlapping CT findings and clinical symptoms, making it hard to distinguish between them. The current study used histogram analysis based on CT images to differentiate between CCM and AICH and test its diagnosis performance.
METHODS: This retrospective study included 158 patients with CCM and 137 patients with AICH. The histograms of brain CT plain scan images of both groups were extracted using Python code and included 18 histogram parameters of the lesions. The most effective parameters were selected by univariate logistic regression analysis and Spearman correlation analysis and included in the final multivariate logistic regression model. The sample was randomly divided into the training set and the validation set by 7:3. The ROC curve was constructed to evaluate the discriminant efficiency of the final logistic regression model in distinguishing between AICH and CCM.
RESULTS: The univariate analysis identified seven significant histogram parameters with the following final logistic regression model: F = 3.731 + 2.6411 × 10-9 × Energy-1.192 × Kurtosis-0.003 × Minimum-1.449 × Skewness + 2.5002 × 10-10 × Total Energy-1.103 × Uniformity+0.009 × Variance. The model showed good diagnostic performance in distinguishing between AICH and CCM, with an AUC of 0.876, sensitivity of 70.8%, and specificity of 91.9% in the training set, and an AUC of 0.870, sensitivity of 82.9%, and specificity of 85.1% in the validation set.
CONCLUSIONS: The histogram analysis of brain CT images can be used as an auxiliary method to distinguish between AICH and CCM effectively.
The invention relates to a natural liquid shampoo containing lily extract comprising compositions with percentage by weight: 0. 05-54563530f lily bulb extract, 1-104565674f lily bulb extract sulphonate, 2-1024521000f poly ethoxy lauryl citric acid disodium succinate, 1. 5-6. 52f cocamidopropyl betaine, 1-64573060f sodium chloride, 0. 05-2. 021472767f antiseptic agent, 0. 5-5153160260f perfume compound, 0. 001-1. 025103530f pigment and 1001f deionized water, the invention has main technical characteristics that the liquid shampoo composed of natural, mild and degradable lily extract lily bulb element and sulfonic acidifying product partly replace the liquid shampoo mixed with the non-degradable chemical synthesis surfactant which has single function and is used normally at present and other ion type and non-ion type surfactant, so that the amount of the common non-degradable surfactant chemical substance can be reduced, the washing waste water pollution can be reduced, and the liquid shampoo can enable the hair to be glossy and facile, the hair is easy to card and the liquid shampoo can remove dandruff and relieve itching.
DSD are conditions in which there is incongruence in an individual's chromosomal, gonadal, or phenotypic sex (refers to sex as determined by an individual's internal or external genitalia and expression of secondary sex characteristics).Different DSD diagnoses have varying degrees of risk for future malignancy. The treating doctor has or will discuss with the participant the risk of developing cancer due to the child's specific diagnosis, and help decide whether this option is in the best interest of the child, and if there are other options to consider (e.g. leaving gonadal tissue in place and monitoring for development of malignancy). If the participant and family have decided to move forward with removal of gonadal tissue for this clinical reason, they will be asked if they would like to have the child participate in this study.

This study seeks to find out if removing gonadal tissue in adolescents and children at risk for losing fertility potential (the ability to have children) and who are scheduled to receive a gonadectomy (removal of gonads) for clinical purposes may preserve, or keep, their ability to have children in the future. Additionally, a primary objective of this study is to use donated research tissue to study long-term ways to preserve and restore reproductive function for children diagnosed with a DSD. Gonadal tissue cryopreservation in patients diagnosed with a DSD is still considered experimental. There have been no reported live births or pregnancies in this population following gonadal tissue cryopreservation at this time.
The usual recommended starting dose is 20 mg once a day given with the evening meal. The recommended dosing range is 10-80 mg/day in single or two divided doses; the maximum recommended dose is 80 mg/day. Doses should be individualized according to the recommended goal of therapy (see NCEP Guidelines and CLINICAL PHARMACOLOGY ). Patients requiring reductions in LDL-C of 20% or more to achieve their goal (see INDICATIONS AND USAGE) should be started on 20 mg/day of lovastatin. A starting dose of 10 mg may be considered for patients requiring smaller reductions. Adjustments should be made at intervals of 4 weeks or more. 

Cholesterol levels should be monitored periodically and consideration should be given to reducing the dosage of lovastatin if cholesterol levels fall significantly below the targeted range.
PROBLEM TO BE SOLVED: To obtain a bathing agent, a skin preparation for external use or a body soap, hardly causing adverse effects and capable of reducing symptoms of atopic dermatitis by including a specific amount of magnesium chloride therein. SOLUTION: This bathing agent for skin, skin preparation for external use or body soap contains (A) 0. 00001-35.3% of magnesium chloride. Besides the prescribed amount of the ingredient A, the agents preferably contain 0.0001-10% each of (B) sodium chloride and (C) potassium chloride. Thereby, the actions of the ingredient A can more be smoothed and the reducing actions on symptoms of atopic dermatitis can be enhanced. Furthermore, the bathing agent of the agents may be capable of regulating the concentration of the ingredient A so as to be 0.00001-0.0002% by adding thereof to warm water in a bathtub.
PROBLEM TO BE SOLVED: To obtain a stable cosmetic material low in irritation to skin and excellent in antibacterial effect, and not polluted by microorganisms such as bacterial and molds by blending a specific plant extract with a specific antiseptic fungicide as a combination. SOLUTION: This antibacterial low irritant cosmetic material contains an extract of an inner seed skin of a ginkgo, and one kind or two or more kinds selected from the group of a para-oxybenzoic acid derivative, phenoxyethanol, photosensitizer 101 (platonin), 201 (pionin), 401 (luminex), hinokithiol, an N-long chain acyl basic amino acid derivative and an acid adduct thereof and zinc oxide. Especially as the N-long chain acyl basic amino acid derivative and the acid adduct thereof, a compound of formula I, II, III [RCO is a fatty acid residue; X is NH2 , OCH3 , etc.; (n) is 3, 4] is preferable. The blending amount of the extract of inner seed skin of the ginkgo is 0.001-10wt.% and those of e.g. an ester of para-oxybenzoic acid and phenoxyethanol are 0.01-0.2wt.% and 0.05-0.3wt.% respectively.
While excessive production of reactive oxygen species (ROS) is a characteristic hallmark of numerous diseases, clinical approaches that ameliorate oxidative stress have been unsuccessful. Here, utilizing multi-omics, we demonstrate that in cardiomyocytes, mitochondrial isocitrate dehydrogenase (IDH2) constitutes a major antioxidative defense mechanism. Paradoxically reduced expression of IDH2 associated with ventricular eccentric hypertrophy is counterbalanced by an increase in the enzyme activity. We unveil redox-dependent sex dimorphism, and extensive mutual regulation of the antioxidative activities of IDH2 and NRF2 by a feedforward network that involves 2-oxoglutarate and L-2-hydroxyglutarate and mediated in part through unconventional hydroxy-methylation of cytosine residues present in introns. Consequently, conditional targeting of ROS in a murine model of heart failure improves cardiac function in sex- and phenotype-dependent manners. Together, these insights may explain why previous attempts to treat heart failure with antioxidants have been unsuccessful and open new approaches to personalizing and, thereby, improving such treatment.
OBJECTIVE: Stress urinary incontinence (SUI) is common among females during functional fitness training, such as CrossFit. The aim of this study was to assess the effect of pelvic floor muscle training (PFMT) on SUI in female functional fitness exercisers.
METHODS: This was an assessor-blinded randomised controlled trial with a PFMT group (n=22) and a control group (n=25). The PFMT group followed a 16-week home-training programme with 3 sets of 8-12 maximum pelvic floor muscle (PFM) contractions daily and weekly follow-up/reminders by phone. The primary outcome was change in a total score of the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI-SF). The secondary outcomes were perceived change of symptoms of SUI, change of PFM strength measured by vaginal manometry and symptoms of anal incontinence (AI) and pelvic organ prolapse (POP).
RESULTS: 47 women, mean age of 33.5 years (SD: 8.1), participated. At 16 weeks, there was a mean difference between groups of -1.4 (95% CI: -2.6 to -0.2) in the change of the ICIQ-UI-SF score in favour of the PFMT group. The PFMT group completed a mean of 70% (SD: 23) of the prescribed protocol. 64% in the PFMT group versus 8% in the control group reported improved symptoms of SUI (p<0.001, relative risk: 7.96, 95% CI, 2.03 to 31.19). There were no group differences in the change of PFM strength or AI/POP symptoms.
CONCLUSION: A 16-week home-training programme of the PFM led to improvements in SUI in female functional fitness exercisers. However, PFM strength and AI and POP symptoms did not improve significantly in the PFMT group compared with the control group.
Organ crosstalk is a complex biological communication between distal organs mediated via cellular, soluble, and neurohormonal actions, based on a two-way pathway. The communication between the central nervous system and peripheral organs involves nerves, endocrine, and immunity systems as well as the emotional and cognitive centers of the brain. Particularly, acute brain injury is complicated by neuroinflammation and neurodegeneration causing multiorgan inflammation, microbial dysbiosis, gastrointestinal dysfunction and dysmotility, liver dysfunction, acute kidney injury, and cardiac dysfunction. Organ crosstalk has become increasingly popular, although the information is still limited. The present narrative review provides an update on the crosstalk between the nervous system and systemic organs after acute brain injury. Future research might help to target this pathophysiological process, preventing the progression toward multiorgan dysfunction in critically ill patients with brain injury.
PROBLEM TO BE SOLVED: To provide systems and methods for facilitating effective self-management of medication treatment by patients.SOLUTION: A Smart Tray 12 monitors and reports to third parties a patient's compliance with medication treatment regimens. Medication containers 34 are provided with electromagnetic tags that provide various information about medicament contained within a respective container 34. The Smart Tray 12 is equipped with a processor and reader that identify medicament(s). Using the retrieved information, the Smart Tray 12 provides visual and/or audio signals to a patient to remind the patient when and how much of various medicaments to take. The Smart Tray 12 also monitors, via the reader, when a medication container 34 is removed, and can communicate with one or more third parties via a computer network. In addition, the Smart Tray 12 can communicate with various appliances and can modify medication regimens for particular medicaments in response to data received from various appliances.
The DUP is an easily measurable indicator, closely linked to prognosis and potentially modifiable, which has led to its wide use to guide the development of early identification programs. Great disparities exist across the world, between different countries and even different regions. France is unusually late, with an average DUP of at least 18 months. Several elements may contribute to explain this state in France: absence of a specific care program for FPE in the vast majority of psychiatric centers, significant stigmatization of psychiatric illnesses, the opacity of psychiatric care and of psychiatric care and lack of knowledge of its organization, in particular by the primary care network that receives patients with PEP in the first line. To date, there is no systematic program in France designed to rapidly identify FPE patients and hasten their specialized care. The objective of this study is to show the impact of an intervention facilitating access to specialized care for PEP on the reduction of DUP.

In addition, this study will seek to analyze the implementation factors of such an intervention in view of a possible generalization and perpetuation.